Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Korean J Intern Med. 2020 Mar;35(2):257-268. doi: 10.3904/kjim.2020.030. Epub 2020 Feb 28.
The increase in lung cancer incidence of Korea has been dampened since 2000; however, increased human lifespan, interest in health care and the widespread implementation of health examinations have resulted in a considerable rise in detection of small lesions that need to be differentiated from lung cancer. Detection of lung cancer at an early stage rather than at a symptomatic advanced stage is also increasing, suggesting that there are increasing diagnostic demands for small peripheral lung lesions. The development of new molecular diagnostics, including next generation sequencing, companion diagnostics that accompany development of new anti-cancer drugs, and re-biopsy for application of new therapeutic modality accelerate the development of lung cancer diagnostics. In this review, we extensively describe the current available diagnostic tools in lung cancer.
自 2000 年以来，韩国的肺癌发病率有所下降；然而，人类寿命的延长、对医疗保健的关注以及健康检查的广泛实施，导致需要从肺癌中区分出来的小病变的检测数量显著增加。早期而非有症状的晚期发现肺癌的情况也在增加，这表明对小周边性肺部病变的诊断需求正在增加。包括下一代测序在内的新型分子诊断技术的发展、伴随新型抗癌药物开发的伴随诊断技术以及新治疗模式应用的再活检，加速了肺癌诊断的发展。在这篇综述中，我们广泛描述了肺癌目前可用的诊断工具。
